Logo
PFE logo
Pfizer Inc.
PFE
24.78 (-2.34%) 0.58
140.89(B)
Health Care
Pharmaceuticals
Pfizer Inc. discovers develops manufactures markets distributes and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas including cardiovascular and migraine under the Eliquis Nurtec ODT/Vydura Zavzpret and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family Abrysvo Nimenrix FSME/IMMUN-TicoVac and Trumenba brands; and COVID-19 prevention and treatment and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz Enbrel Inflectra Litfulo Velsipity and Cibinqo brands; amyloidosis hemophilia endocrine diseases and sickle cell disease under the Vyndaqel family Oxbryta BeneFIX Somavert Ngenla and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon Medrol Zavicefta Zithromax Octagam and Panzyga brands; and biologics small molecules immunotherapies and biosimilars under the Ibrance Xtandi Padcev Adcetris Inlyta Lorbrena Bosulif Tukysa Braftovi Mektovi Orgovyx Elrexfio Tivdak and Talzenna brands. In addition the company involved in the contract manufacturing business. It serves wholesalers retailers hospitals clinics government agencies pharmacies individual provider offices retail pharmacies and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York New York.

My Quality Checklist

5Y Shares Out Change < 0%
ROIC > 10%
Debt/Equity < 1
Current Ratio > 1
Quick Ratio > 1
Net Margin > 10%
Past Net Income CAGR > 0%
Est. EPS Growth > 5%
0.0%of Portfolio

My holdings

Day change:
Total change:
Shares:
Cost basis:
Compare
Market cap:$140.89(B)
EV:$190.00(B)
Total Equity:$89.01(B)
Div. yield:6.86%
Earnings date:Nov-04-2025
P/E:13.04
P/E (fwd):8.05
P/FCF:11.32
P/S:2.20
P/B:1.59
EPS:$1.9
EPS (fwd):$3.1
FCF/share:$2.2
Book value/share:$15.6
Dividend/share:$1.7
ROIC:7.0%
ROA:5.1%
ROE:12.2%
Gross margin:73.8%
Net margin:16.8%
Valuation Summary TTM Financials Growth Estimates Historical Data KPIs Competitors & Peers Ownership Tools

PFE Valuation & Price Targets

Current Price
$24.8
Day change: -2.34%
PEvaluation
N/A
N/A
Analyst targets
N/A
N/A
DCF (2-stage)
N/A
N/A
DCF (simple)
N/A
N/A
DCF (exit mult.)
N/A
N/A
EPS growth
N/A
N/A
Revenue growth
N/A
N/A
Peter Lynch FV
N/A
N/A
Graham No.
N/A
N/A
DDM
N/A
N/A

PEvaluation

62% undervalued
Low
$30.1
Mid
$40.1
High
$50.2
Current price
$24.8
Fair P/E
Margin of safety
EPS
Market Model
Shares outstan...ROICRevenue growthDebt/FCFAssets/Liabili...
Economic moat: Wide

EPS Estimates

LowAvgHigh#
FY+12.93.13.322
FY+23.03.23.621
FY+32.73.13.819
FY+42.52.73.210
FY+52.12.42.910

Analyst Price Targets

15% undervalued
Low
$24.0
Mid
$28.5
High
$36.0
Current price
$24.8

Analyst Recommendations

Strong Buy1
Buy7
Hold15
Sell1
Strong Sell0

2-stage DCF

First Stage Duration
Starting Free Cash Flow
First Stage Growth Rate
LowMidHigh
Terminal Growth Rate
LowMidHigh
Discount Rate

Discounted Cash Flow

Forecast years
Terminal Growth Rate
LowMidHigh
Discount Rate
Free cash flow estimates:
Y+1 est.
Y+2 est.
0.00%
Y+3 est.
0.00%
Y+4 est.
0.00%
Y+5 est.
0.00%

Discounted Cash Flow (exit mult.)

Forecast years
Exit FCF Multiple
LowMidHigh
Discount Rate
Free cash flow estimates:
Y+1 est.
Y+2 est.
0.00%
Y+3 est.
0.00%
Y+4 est.
0.00%
Y+5 est.
0.00%

EPS Growth

Forecast years
Starting EPS
EPS Growth Rate
LowMidHigh
Final P/E
LowMidHigh
Discount Rate

Revenue Growth Valuation

Forecast Years
Base Revenue
Revenue Growth Rate
LowMidHigh
Final Net Margin
LowMidHigh
Final P/E Ratio
LowMidHigh
Discount Rate

Peter Lynch Fair Value

Earnings Per Share
Growth Rate

Graham Formula

Earnings Per Share
EPS Growth (7-10 years)
Government Bond Rate

Dividend Discount Model

Annual Dividend
First Stage Length (Years)
First Stage Growth Rate
Final Growth Rate
Discount Rate

TTM Financials

Income (TTM)

RevenueGrossNet
Revenue$63.83(B)
Gross profit$47.12(B)
EBITDA$24.51(B)
Net income$10.75(B)
Gross margin73.8%
Operating margin26.1%
Net margin16.8%
Shares outstanding:5.69(B)

Balance sheet

Cash & ST inv.Other ST assetsLong term assetsCurrent liabilitiesLong term debtOther LT liabilitiesEquity
Total assets$206.09(B)
Current assets$43.70(B)
Total liabilities$117.08(B)
Current liabilities$37.73(B)
Cash & Short-term inv.$13.25(B)
Long-term debt$57.73(B)
Total intangibles$121.70(B)
PP&E$18.78(B)

Cash flow (TTM)

CFOCFICFF
FCF$12.44(B)
CapEx$-2.75(B)
Dividends paid$-9.64(B)
Stock issued$0
Stock repurchased$0
Stock-based comp.$840.00(M)
Debt issued$6.58(B)
Debt repaid$-14.71(B)

Per share data (TTM)

Price: $24.8
Revenue: $11.3 (2.2x | 45.4%) Gross profit: $8.29 (3.0x | 33.4%) Earnings: $1.90 (13.0x | 7.7%)
FCF: $2.19 (11.3x | 8.8%) Stock-based Comp.: $0.15 (167.7x | 0.6%) CapEx.: $0.48 (51.2x | 2.0%) Dividend: $1.70 (14.6x | 6.9%)
Total Assets: $36.2 (0.7x | 146.3%) Total Liabilities: $20.6 (1.2x | 83.1%) Book Value: $15.6 (1.6x | 63.0%) Cash & ST inv.: $2.33 (10.6x | 9.4%) Debt: $10.2 (2.4x | 41.0%)
Earnings FY+1: $3.08 (8.0x | 12.4%) Earnings FY+2: $3.18 (7.8x | 12.8%) Earnings FY+3: $3.12 (7.9x | 12.6%) Earnings FY+4: $2.73 (9.1x | 11.0%) Earnings FY+5: $2.42 (10.2x | 9.8%)
FCF FY+1: $2.17 (11.4x | 8.8%) FCF FY+2: $3.25 (7.6x | 13.1%) FCF FY+3: $3.29 (7.5x | 13.3%) FCF FY+4: $3.03 (8.2x | 12.2%) FCF FY+5: $2.75 (9.0x | 11.1%)

Growth Estimates

Revenue

CAGR: -3.7%
FY+1FY+2FY+3FY+4FY+5
FY+1$63.20(B)
FY+2(-0.8%)$62.71(B)
FY+3(-2.3%)$61.27(B)
FY+4(-6.0%)$57.57(B)
FY+5(-5.6%)$54.36(B)

Net Income

CAGR: -5.3%
FY+1FY+2FY+3FY+4FY+5
FY+1$17.67(B)
FY+2(+3.3%)$18.24(B)
FY+3(-2.4%)$17.81(B)
FY+4(-11.8%)$15.72(B)
FY+5(-9.6%)$14.21(B)

EPS

CAGR: -5.9%
FY+1FY+2FY+3FY+4FY+5
FY+1$3.08
FY+2(+3.2%)$3.18
FY+3(-1.9%)$3.12
FY+4(-12.5%)$2.73
FY+5(-11.4%)$2.42

FCF per share

CAGR: 6.1%
FY+1FY+2FY+3FY+4FY+5
FY+1$2.17
FY+2(+49.9%)$3.25
FY+3(+1.0%)$3.29
FY+4(-7.7%)$3.03
FY+5(-9.3%)$2.75

Historical Financials

Showing limited histrical data.
TTM (Y)TTM (Q)FYFQ
Income(show more...)
Q2'20 (TTM)Q2'21 (TTM)Q2'22 (TTM)Q2'23 (TTM)Q2'24 (TTM)Q2'25 (TTM)0.020.0(B)40.0(B)60.0(B)80.0(B)100.0(B)
Revenue Operating Income Net IncomeCOGSGross ProfitTotal OpEx.R&DSG&AInterest ExpenseInterest IncomePre-tax incomeIncome tax
Cash flow(show more...)
Q2'20 (TTM)Q2'21 (TTM)Q2'22 (TTM)Q2'23 (TTM)Q2'24 (TTM)Q2'25 (TTM)0.05.0(B)10.0(B)15.0(B)20.0(B)25.0(B)
Stock-based Comp. FCFCFONet IncomeD&ACFFStock IssuedStock RepurchasedDebt IssuedDebt RepaidDividend PaidCFIAcquisitionsDivestituresCapital Expenditures
Balance sheet(show more...)
Q2'20 (TTM)Q2'21 (TTM)Q2'22 (TTM)Q2'23 (TTM)Q2'24 (TTM)Q2'25 (TTM)0.050.0(B)100.0(B)150.0(B)200.0(B)
Total Assets Total LiabilitiesCurrent assetsCash and EquivalentsShort-term investmentsInventoriesReceivablesNon-current assetsNet PP&EIntangible AssetsGoodwillCurrent liabilitiesShort-Term DebtAccounts payableNon-current liabilitiesLong-Term DebtTotal Equity
Per share data(show more...)
Q2'20 (TTM)Q2'21 (TTM)Q2'22 (TTM)Q2'23 (TTM)Q2'24 (TTM)Q2'25 (TTM)0.01.02.03.04.05.0
EPS (Basic) FCF/Share Dividend/ShareEPS (Diluted)Book value/ShareCash & ST inv./ShareDebt/Share
Ratios(show more...)
Q2'20 (TTM)Q2'21 (TTM)Q2'22 (TTM)Q2'23 (TTM)Q2'24 (TTM)Q2'25 (TTM)0.05.010.015.020.025.0
P/E P/S EV/EarningsP/FCFP/BEV/FCFDebt/EquityPayout ratio
Margins(show more...)
Q2'20 (TTM)Q2'21 (TTM)Q2'22 (TTM)Q2'23 (TTM)Q2'24 (TTM)Q2'25 (TTM)0%20%40%60%
Net Income Margin Operating Margin Gross MarginEBITDA MarginFCF Margin
Returns(show more...)
Q2'20 (TTM)Q2'21 (TTM)Q2'22 (TTM)Q2'23 (TTM)Q2'24 (TTM)Q2'25 (TTM)0%5%10%15%20%
ROIC ROAROCEROE
Shares outstanding(show more...)
Q2'20 (TTM)Q2'21 (TTM)Q2'22 (TTM)Q2'23 (TTM)Q2'24 (TTM)Q2'25 (TTM)0.01.0(B)2.0(B)3.0(B)4.0(B)5.0(B)
Shares (Basic)Shares (Diluted)
Market Cap.(show more...)
Q2'20 (TTM)Q2'21 (TTM)Q2'22 (TTM)Q2'23 (TTM)Q2'24 (TTM)Q2'25 (TTM)0.050.0(B)100.0(B)150.0(B)200.0(B)250.0(B)
Market Cap.

KPIs

No KPI data available yet!

Competitors & Peers

Ownership

Major holders

*Excludes indirect insider ownership

Insiders: 0.07%
Institutions: 67.10%
Other: 32.83%

Institutional ownership

9.38% Vanguard Group Inc8.70% Blackrock Inc.5.21% State Street Corporati...2.24% Geode Capital Manageme...1.65% NORGES BANK1.35% Wellington Management ...1.33% Massachusetts Financia...1.23% Morgan Stanley1.11% Northern Trust Corpora...0.96% State Farm Mutual Auto...33.94% Others

Trading Summary

In the past year, insiders have bought $527312 worth of the company's stock, and sold $64825.

Congress members have bought between $88018 - $445000 worth of the company's stock, and sold between $100016 - $450000.

Insider transactions

$0.002025-11$0.00
$0.002025-10$0.00
$0.002025-09$0.00
$0.002025-08$0.00
$0.002025-07$0.00
$0.002025-06$0.00
$0.002025-05$0.00
$0.002025-04$0.00
$648252025-03$0.00
$0.002025-02$499072
$0.002025-01$0.00
$0.002024-12$0.00
$0.002024-11$0.00
DateSharesTotal ($)Price ($)NameTitle
Sell2025-03-042,50064,82525.9DAMICO JENNIFER B.Officer
Grant2025-03-045,58300.0DAMICO JENNIFER B.Officer
Grant2025-02-2719,054596,58131.3SAHNI PAYALOfficer
Grant2025-02-2748,4191,515,99931.3MCDERMOTT MICHAELOfficer
Grant2025-02-2722,416701,84531.3DAMICO JENNIFER B.Officer
Grant2025-02-27582,82318,248,18831.3BOURLA ALBERTChief Executive Officer
Grant2025-02-27156,9144,912,97731.3LANKLER DOUGLAS MOfficer
Grant2025-02-2772,6292,274,01431.3FONSECA LIDIA PH.D.Officer
Grant2025-02-2785,1822,667,04831.3SUSMAN SALLYOfficer
Grant2025-02-2717,45000.0BOSHOFF CHRISTOFFELOfficer
Grant2025-02-269,68700.0BOSHOFF CHRISTOFFELOfficer
Grant2025-02-2111,125335,64130.2MCDERMOTT MICHAELOfficer
Grant2025-02-218,741263,71630.2BOSHOFF CHRISTOFFELOfficer
Grant2025-02-218,741263,71630.2BOSHOFF CHRISTOFFELOfficer
Grant2025-02-218,741263,71630.2DAMICO JENNIFER B.Officer
Grant2025-02-2112,714383,58130.2SAHNI PAYALOfficer
Grant2025-02-21238,3997,192,49830.2BOURLA ALBERTChief Executive Officer
Grant2025-02-2185,8242,589,31030.2LANKLER DOUGLAS MOfficer
Grant2025-02-2163,5731,917,99730.2SUSMAN SALLYOfficer
Buy2025-02-1319,457499,07225.6BLAYLOCK RONALD EDirector
Buy2024-10-301,00028,24028.2GOTTLIEB SCOTTDirector

Congressional trading

$0.002025-11$0.00
$0.002025-10$0.00
$0.002025-09$0.00
$0.002025-08$0.00
$0.002025-07$0.00
$160012025-06$16001
$0.002025-05$56502
$1380032025-04$8001
$405012025-03$8001
$160012025-02$105502
$240022025-01$24002
$0.002024-12$0.00
$325012024-11$16001
DatePoliticianPartyChamberAmount ($)
Buy2025-06-20Ro KhannaDHouse$1,001 - $15,000
Buy2025-06-20Ro KhannaDHouse$1,001 - $15,000
Sell2025-06-03Josh GottheimerDHouse$1,001 - $15,000
Sell2025-06-03Ron WydenDSenate$1,001 - $15,000
Buy2025-05-30Gilbert Ray Cisneros, Jr.DHouse$1,001 - $15,000
Buy2025-05-28Ro KhannaDHouse$1,001 - $15,000
Buy2025-05-28Ro KhannaDHouse$1,001 - $15,000
Buy2025-05-15Rob BresnahanRHouse$15,001 - $50,000
Buy2025-04-29Gilbert Ray Cisneros, Jr.DHouse$1,001 - $15,000
Sell2025-04-21Bruce WestermanRHouse$1,001 - $15,000
Sell2025-04-15Ro KhannaDHouse$15,001 - $50,000
Sell2025-04-15Ro KhannaDHouse$15,001 - $50,000
Sell2025-04-11Jefferson ShreveRHouse$15,001 - $50,000
Sell2025-04-08Rob BresnahanRHouse$15,001 - $50,000
Sell2025-03-31Gilbert Ray Cisneros, Jr.DHouse$15,001 - $50,000
Sell2025-03-10Carol D. MillerRHouse$1,001 - $15,000
Buy2025-03-03Bruce WestermanRHouse$1,001 - $15,000
Buy2025-02-26Gilbert Ray Cisneros, Jr.DHouse$1,001 - $15,000
Buy2025-02-25Rob BresnahanRHouse$15,001 - $50,000
Buy2025-02-24Jefferson ShreveRHouse$15,001 - $50,000
Buy2025-02-24Jefferson ShreveRHouse$15,001 - $50,000
Sell2025-02-13John BoozmanRSenate$1,001 - $15,000
Sell2025-02-12Julie JohnsonDHouse$1,001 - $15,000
Sell2025-01-24Gilbert Ray Cisneros, Jr.DHouse$1,001 - $15,000
Buy2025-01-22Ro KhannaDHouse$1,001 - $15,000
Buy2025-01-22Ro KhannaDHouse$1,001 - $15,000
Buy2025-01-17Ro KhannaDHouse$1,001 - $15,000
Sell2025-01-15Julie JohnsonDHouse$1,001 - $15,000
Sell2025-01-15Julie JohnsonDHouse$1,001 - $15,000
Sell2024-11-15Ro KhannaDHouse$15,001 - $50,000
Buy2024-11-13Ro KhannaDHouse$1,001 - $15,000
Buy2024-11-13Ro KhannaDHouse$1,001 - $15,000
Buy2024-10-21Laurel M. LeeRHouse$15,001 - $50,000
Sell2024-10-15Greg LandsmanDHouse$1,001 - $15,000

Summary

Tools

Dividend Income

Investment Amount
Dividend Yield
What is the Dividend Income Calculator?

The Dividend Income Calculator helps you estimate the yearly, quarterly, monthly, and daily income of your investments.

How to Use This Calculator?

Enter the dividend yield and the invested amount. Optionally, preload stock data to automatically fetch the dividend yield.

Required Investment

Dividend Yield
Desired Yearly Payout
Desired Quarterly Payout
Desired Monthly Payout
What is the Required Investment Calculator?

The Required Investment Calculator helps you determine the amount of money you need to invest in a stock to achieve a desired dividend.

How to Use This Calculator?

Enter the dividend yield and your desired dividend income. Optionally, preload stock data to automatically fetch the dividend yield.

Future Dividend Yield

Base Dividend
Current Price
Number of Years
Dividend Growth Rate
What is the Future Yield Calculator?

The Future Yield Calculator helps you estimate the future dividend yield of a stock based on its current dividend, price, and expected dividend growth rate.

How to Use This Calculator?

Enter the base dividend, current price, number of years, and dividend growth rate. Optionally, preload stock data to automatically fetch the dividend and price. The calculator will display the current yield and the projected future yield.

Future Dividend Income

Base Dividend
Number of Years
Dividend Growth Rate
What is the Future Dividend Income Calculator?

The Future Dividend Income Calculator helps you estimate the future dividend income from your investments based on the current dividend yield and expected growth rate.

How to Use This Calculator?

Enter the current dividend yield, expected growth rate, and investment duration. Optionally, preload stock data to automatically fetch the dividend yield.

(C) PEVALUATOR
About
Terms & privacy
Price charts & news courtesy of TradingView
Blog
Contact